FDA Approves TECVAYLI — Janssen Biotech, Inc.

# FDA Approves Janssen Biotech's TECVAYLI for Multiple Myeloma Treatment The FDA has approved Janssen Biotech's TECVAYLI (teclistamab-cqyv), a subcutaneous bispecific antibody, expanding the company's oncology portfolio and positioning it to capture market share in the competitive multiple myeloma space. The approval could drive significant revenue growth for Janssen while establishing a new treatment option for patients with relapsed or refractory disease.